These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28974323)

  • 1. Synthesis and photophysical properties of a fluorescent cyanoquinoline probe for profiling ERBB2 kinase inhibitor response.
    Lee H; Landgraf R; Wilson JN
    Bioorg Med Chem; 2017 Nov; 25(21):6016-6023. PubMed ID: 28974323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emission tuning of fluorescent kinase inhibitors: conjugation length and substituent effects.
    Dhuguru J; Liu W; Gonzalez WG; Babinchak WM; Miksovska J; Landgraf R; Wilson JN
    J Org Chem; 2014 Jun; 79(11):4940-7. PubMed ID: 24784897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding-induced, turn-on fluorescence of the EGFR/ERBB kinase inhibitor, lapatinib.
    Wilson JN; Liu W; Brown AS; Landgraf R
    Org Biomol Chem; 2015 May; 13(17):5006-11. PubMed ID: 25820099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorescent Kinase Probes Enabling Identification and Dynamic Imaging of HER2(+) Cells.
    Lee H; Liu W; Brown AS; Landgraf R; Wilson JN
    Anal Chem; 2016 Dec; 88(23):11310-11313. PubMed ID: 27934102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.
    Petrov KG; Zhang YM; Carter M; Cockerill GS; Dickerson S; Gauthier CA; Guo Y; Mook RA; Rusnak DW; Walker AL; Wood ER; Lackey KE
    Bioorg Med Chem Lett; 2006 Sep; 16(17):4686-91. PubMed ID: 16777410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
    Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
    Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors.
    Alsaid MS; Al-Mishari AA; Soliman AM; Ragab FA; Ghorab MM
    Eur J Med Chem; 2017 Dec; 141():84-91. PubMed ID: 29028534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents.
    Sadek MM; Serrya RA; Kafafy AH; Ahmed M; Wang F; Abouzid KA
    J Enzyme Inhib Med Chem; 2014 Apr; 29(2):215-22. PubMed ID: 23402383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
    Suzuki T; Fujii A; Ochi H; Nakamura H
    J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fluorescent reporter of ATP binding-competent receptor kinases.
    Sicard R; Dhuguru J; Liu W; Patel N; Landgraf R; Wilson JN
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5532-5. PubMed ID: 22868229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: Design, synthesis, kinase assay, cell-based assay, and molecular docking.
    Elkamhawy A; Farag AK; Viswanath AN; Bedair TM; Leem DG; Lee KT; Pae AN; Roh EJ
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5147-54. PubMed ID: 26475520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Substituted quinazoline derivatives as novel EphA2 receptor tyrosine kinase inhibitors.
    Lim CJ; Oh KS; Ha JD; Lee JH; Seo HW; Chae CH; Kim DG; Lee MJ; Lee BH
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4080-3. PubMed ID: 25124116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors.
    Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM
    Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor.
    Jani JP; Finn RS; Campbell M; Coleman KG; Connell RD; Currier N; Emerson EO; Floyd E; Harriman S; Kath JC; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Ralston S; Rossi AM; Steyn SJ; Wagner L; Winter SM; Bhattacharya SK
    Cancer Res; 2007 Oct; 67(20):9887-93. PubMed ID: 17942920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A subnanomolar fluorescent probe for protein kinase CK2 interaction studies.
    Enkvist E; Viht K; Bischoff N; Vahter J; Saaver S; Raidaru G; Issinger OG; Niefind K; Uri A
    Org Biomol Chem; 2012 Nov; 10(43):8645-53. PubMed ID: 23032938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.